Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population-Reference-Cited by-同舟云学术

Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population

Published:2024-08 Issue:7 Volume:48 Page:102389
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Rashu Elias Badal^ORCID,Werge Mikkel Parsberg,Hetland Liv Eline,Thing Mira,Nabilou Puria,Kimer Nina,Junker Anders Ellekaer,Jensen Anne-Sofie Houlberg,Nordestgaard Børge Grønne,Stender Stefan,Gluud Lise Lotte

Publisher

Elsevier BV

Reference37 articles.

1. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;J Hepatol,2016

2. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association;Chalasani;Hepatology,2012

3. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?;Blond;Diabetologia,2017

4. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;Byrne;Diabetologia,2016

5. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD;Hagström;J Hepatol,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mild-moderate alcohol consumption and diabetes are associated with liver fibrosis in patients with biopsy-proven MASLD;Frontiers in Pharmacology;2024-07-31